Alector Inc ALEC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
5.44UNCH (UNCH)
Volume
19,652
Close
5.44quote price arrow down-0.05 (-0.91%)
Volume
524,929
52 week range
3.66 - 9.06
Loading...
  • Open5.50
  • Day High5.53
  • Day Low5.30
  • Prev Close5.49
  • 52 Week High9.06
  • 52 Week High Date08/04/23
  • 52 Week Low3.66
  • 52 Week Low Date11/16/23

Key Stats

  • Market Cap524.332M
  • Shares Out96.38M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change-31.83

KEY STATS

  • Open5.50
  • Day High5.53
  • Day Low5.30
  • Prev Close5.49
  • 52 Week High9.06
  • 52 Week High Date08/04/23
  • 52 Week Low3.66
  • 52 Week Low Date11/16/23
  • Market Cap524.332M
  • Shares Out96.38M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change-31.83

RATIOS/PROFITABILITY

  • EPS (TTM)-1.39
  • P/E (TTM)-3.92
  • Fwd P/E (NTM)-2.61
  • EBITDA (TTM)-139.425M
  • ROE (TTM)-66.65%
  • Revenue (TTM)96.406M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-125.11%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Alector Inc

 

Profile

MORE
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in...
Arnon Rosenthal Ph.D.
Chief Executive Officer, Co-Founder, Director
Saraswati Kenkaremitra Ph.D.
President, Head - Research and Development
Marc Grasso M.D.
Chief Financial Officer
Address
131 OYSTER POINT BLVD., SUITE 600
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
YMAB
Y-mAbs Therapeutics Inc
11.60-0.25-2.11%
URGN
Urogen Pharma Ltd
13.22+0.01+0.08%
EDIT
Editas Medicine Inc
5.62-0.27-4.58%
NKTR
Nektar Therapeutics
1.75-0.05-2.50%
TBPH
Theravance Biopharma Inc
9.29-0.31-3.23%